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Abstract
Background: Combination therapy with prednisone or etanercept may induce earlier and/or more improvement in
disease activity in Disease Modifying Anti Rheumatic Drug (DMARD) naïve non-systemic Juvenile Idiopathic Arthritis
(JIA) patients. Here we present three months clinical outcome of initial treatments of the BeSt-for-Kids study.
Methods: Included patients were randomized to either: 1. initial DMARD-monotherapy (sulfasalazine (SSZ) or
methotrexate (MTX)), 2. Initial MTX / prednisolone-bridging, 3. Initial combination MTX/etanercept. Percentage
inactive disease, adjusted (a) ACR Pedi30, 50 and 70 and JADAS after 6 and 12 weeks of treatment (intention to
treat analysis) and side effects are reported.
Results: 94 patients (67% girls, 32 (arm 1), 32 (arm 2) and 30 (arm 3) with median (InterQuartileRange) age of 9.1 (4.7-12.9)
years were included. 38% were ANA positive, 10 had oligo-articular disease, 68 polyarticular JIA and 16 psoriatic arthritis.
Baseline median (IQR) ACRpedi-scores: VAS physician 49 (40-58) mm, VAS patient 54 (37-70) mm, ESR 6.5 (2-14.8)mm/hr,
active joint count 8 (5-12), limited joint count 3 (1-5), CHAQ score 0.88 (0.63-1.5). In arm 1, 17 started with
MTX, 15 with SSZ.
After 3 months, aACR Pedi 50 was reached by 10/32 (31%), 12/32(38%) and 16/30 (53%) (p = 0.19) and aACR
Pedi 70 was reached by 8/32 (25%), 6/32(19%) and 14/30(47%) in arms 1-3 (p = 0.04). Toxicity was similar. Few
serious adverse events were reported.
Conclusion: After 3 months of treatment in a randomized trial, patients with recent-onset JIA achieved
significantly more clinical improvement (aACRPedi70) on initial combination therapy with MTX / etanercept
than on initial MTX or SSZ monotherapy.
Trial registration: NTR1574. Registered 3 December 2008.
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Introduction
Juvenile Idiopathic Arthritis (JIA) is the most com-
mon auto-immune disease in children [1] except for
systemic JIA which is nowadays viewed as an auto-
inflammatory disease [2]. Many children suffer from
chronic functional disability and damage due to pro-
longed inflammation [3]. The ILAR criteria divide the
heterogeneous disease in 7 categories [4]. Prognosis is
difficult to predict and even oligoarticular disease can
have a debilitating course [5]. Nowadays an expanding
repertoire of disease modifying antirheumatic drugs
(DMARD) including biologicals is available for treat-
ment [6]. Evidence-based information is available on
the efficacy of individual products [7–15] but know-
ledge on therapeutic strategies in children is still
scarce [16, 17]. As shown in the BeSt study in
rheumatoid arthritis patients[18], it is likely and was
illustrated previously that also in JIA a window-of-
opportunity exists where the disease is most respon-
sive to treatment and susceptible for permanent
suppression [11, 16, 17, 19]. Additionally we know
that an early response to therapy is related to a better
outcome [20, 21].
In the current study we investigate which of 3 treat-
ment strategies is most effective, fast-acting and safe in a
randomized clinical trial comparing three initial therap-
ies: arm 1 initial monotherapy with MTX or SSZ; arm 2
initial combination therapy with MTX and prednisolone
and arm 3 initial combination therapy with etancercept
and MTX. We hypothesized that compared to initial
monotherapy (arm 1) with sulphasalazine or methotrex-
ate or initial combination therapy with MTX/prednisone
(arm 2) early treatment with etanercept and methotrex-
ate (arm 3) would lead to significantly more and earlier
clinical inactive disease.
Methods
Patients
Patients diagnosed as DMARD-naive JIA, either
rheumatoid factor negative polyarticular, oligoarticular
JIA, or juvenile psoriatic arthritis, in need of systemic
DMARD therapy according to treating physician, with
less than 18 months of complaints, aged between 2-
16, were eligible at 5 participating sites in the
Netherlands. Patients suffering from rheumatoid
factor-positive JIA are preferably treated with combin-
ation therapy from the start and were excluded [17]
as well as systemic JIA and Enthesitis Related JIA
since they comprise of JIA patients with different
clinical features potentially increasing heterogeneity.
Patients with JIA related uveitis were excluded due to
possible exposure to etanercept which is known to be
less effective in uveitis treatment [22–26].
Study design
Data are collected through the BeSt for Kids study, an
investigator-initiated multicentre randomised single
blinded clinical trial which will have 2 years follow-up in
three treatment arms in a treat-to-target setting. The
study was approved by the Medical Ethical Committee
of the Leiden University Medical Center and local
Ethical Committees prior to start at each study site.
Written Informed consent was obtained from patients
above 12 years of age and parents of all participating
patients. Patients were enrolled and randomly assigned
to one of three treatment arms by variable block
randomization, stratified per center, as oligo or polyarti-
cular disease.
Initial treatments
Patients assigned to arm 1 started with Sulphasalazine
50 mg/kg up to 2000 mg/day or MTX10mg/m2/wk or-
ally or subcutaneous (sc)(max 25 mg/wk).
Patients assigned to arm 2 started with MTX
10 mg/m2/wk orally or sc (max 25 mg/wk) in com-
bination with prednisolone orally 0,5 mg/kg for four
weeks, tapering by 1 week 0,25 mg/kg and 1 week
0,125 mg/kg, then stop.
Patients assigned to arm 3 started with a combination
of etanercept 0,8 mg/kg/wk sc and MTX 10 mg/m2/wk
orally or sc (max25mg).
Prior to etanercept treatment, all children were
screened for tuberculosis by a purified protein derivative
skin test and a chest radiograph. All tested negative.
Concomitant treatment with non-steroidal anti-
inflammatory drugs (NSAIDs) and intra-articular gluco-
corticoid injections were permitted without a maximum
and registered per strategy. Other parenteral glucocorti-
coids were not allowed. The use of DMARD or oral glu-
cocorticoids was only permitted as dictated by the
treatment protocol. All protocol deviations were re-
corded. All patients received folic acid during MTX
treatment.
Assessment of disease activity: definition of improvement
and inactive disease
The core set criteria [27] were scored at 6 weeks and
3 months by a research nurse, physical therapist or
pediatric rheumatologist who remained blinded to the
allocated treatment group during study period. Since
the protocol was written in 2008 inactive disease on
medication was defined based on the modified Wal-
lace 2004 definition [28] instead of the current defin-
ition [29]. Based on previous results [30] we stated
that a doctor’s overall assessment score below 10 mm
(instead of 0 mm) on the VAS indicated no disease
activity provided that all other parameters as defined
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[28] indicated inactive disease. We defined ESR values
under 16 mm/h as normal.
Definition of improvement was based on ACRPedi30/50/
70% [27]. Changes in outcomes that remained within nor-
mal limits (ESR ≤ 16 mm/h and VAS physician < 10 mm)
were not taken into account in ACRPedi calculations and
were corrected for, resulting in adjusted (aACRPedi30/50/
70%) scores.
Juvenile Arthritis Disease Activity Score (JADAS)-10
score were calculated as described previously [31].
Delta JADAS10 was defined as the difference between
JADAS10 score at subsequent visits with baseline
score.
Toxicity
At each visit (baseline, 6 weeks, 12 weeks), laboratory
tests were performed as clinically indicated: complete
blood count, liver and kidney function. The treating
physician recorded all adverse events (AEs), serious ad-
verse events (SAEs), and if necessary, made treatment
adjustments in accordance to the protocol. SAEs were
defined as any adverse reaction resulting in any of the
following outcomes: a life threatening condition or
death, a significant or permanent disability, a malig-
nancy, and (prolonged) hospitalization.
Sample size calculations
Expected percentages of time to inactive disease were
extrapolated from available literature in 2008 [9, 11, 13]
and based on estimation. For the comparison of arm 1
versus arm 3, with power > 90% a difference of 10% in
arm 1 versus 60% in arm 3 can be detected with two
groups of 30 patients assuming a hazard ratio of 8.70, a
drop-out rate 20%, a percentage that switched groups
20%, an alpha 0.05, by two-sided log rank test. Based on
analogous calculations (PASS2008) two groups of 45 and
54 patients were needed to detect differences between
arm 2 versus arm 3 and between arm 1 versus arm 2.
Initially 60 patients per arm was aimed for. Due to slow
inclusion rate, the study protocol was amended in 2012
to include 3 groups of 30 patients, leaving enough power
to compare arm 1 versus arm 3.
Statistical methods
Missing data in core set variables were scarce (<1%).
All available data were included for intention-to-treat
analysis. Last observation carried forward was used to
deal with few missing values (n = 5). Student’s t-test
was used to compare continuous normally distributed
variables between groups. Non-parametric Mann
Whitney U tests were used otherwise. For dichotom-
ous variables, Pearson’s chi-square test was used. A
two-tailed probability value of P < 0.05 was considered
statistically significant. P-values were not adjusted for
multiple statistical tests.
The Trial was registered in the Dutch Trial Register
number 1574.
Results
Baseline characteristics
Baseline demographics and disease characteristics of the
three groups showed no statistically significant differ-
ences and are summarized in Table 1.
Outcome
Figure 1 shows the flow diagram of the study. 94 pa-
tients with early JIA, with a median duration between
diagnosis and inclusion of 6 weeks (IQR 3-14) and a me-
dian duration of symptoms of 7.5 months (IQR 5-12,5),
were randomized to one of three treatment groups: 32
patients assigned to monotherapy (arm 1), 32 patients
assigned to combination with methotrexate and
prednisone-bridging (arm2) and 30 patients were
assigned to combination of etanercept and methotrexate
(arm 3).
Adjusted ACRPedi30/50/70 and early inactive disease
Results are summarized in Table 2. From the patients in
inactive disease according to our definition: 11/21(52%)
had a VAS physician of 0 mm, while 10/21(48%) had a
VAS that was scored >0 mm, the average was 3.8 mm.
Medication changes and protocol violations
Medication changes and protocol violations are sum-
marized in Table 3. In arm 1 and arm 2 more medi-
cation changes occurred compared to arm 3 in the
first three months of therapy due to adverse events
(n = 5). Use of prednisone outside of protocol oc-
curred 3 times in arm 1. Of the 15 patients who
started on SSZ, 3 switched to MTX after 6 weeks due
to nausea, malaise, headache.
Adverse events
A summary of toxicity is given in Table 4. A total of 28%
(26/94) of all patients experienced ≥ one AEs: 7/32(22%),
9/32 (28%) and 10/30(33%). Gastro-intestinal symptoms
were most frequently reported and were observed 7/32
(22%), 14/32 (44%) and 9/30(28%) in arm 1, 2 and 3. Sec-
ond mostly reported were mild infectious complications
(8/32 (25%)in arm 1, 6/32 (19%) in arm 2 and 13/30 (43%)
in arm 3) with 8 upper respiratory tract infections docu-
mented in arm 3. Hospital admissions accounted for 3
SAEs in the first three months. One SAE due to viral
pneumonia with mild oxygen demand ( on SSZ, arm 1),
one patient (on MTX, arm 1) suffered from prolonged
vomiting which resolved after admission and stopping of
MTX. One patient (on MTX, arm 2) had fever of
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unknown origin while on MTX and was observed shortly
without additional therapy.
Discussion
In the BeSt for Kids study, early clinical improvement
in patients with early JIA was the aim of the three ini-
tial therapies: initial monotherapy with MTX or SSZ,
MTX with initial bridging with prednisone, and MTX
with etanercept. We found comparable outcomes in
all three arms, with the exception that initial
combination therapy with etanercept /MTX resulted
in a significantly higher percentage of children that
had reached aACRPedi70 after three months of treat-
ment. All three groups already after 6 weeks showed
improvement, and there was a trend for further
improvement in arms 1 and 3, possibly related to dis-
continuation of bridging therapy with prednisone in
arm 2. The effect of prednisone bridging is visible in
high aACRPedi 30/50/70% responses after six weeks
but improvements diminished after tapering and stop-
ping of prednisone.
Medication changes had occurred more often in
arm 1 and arm 2 as compared to arm 3. Toxicity was
comparable and acceptable. A subgroup of arm 1
Table 1 Baseline demographics and disease characteristics
Arm 1
MTX or SSZ monotherapy
(n = 32)
Arm 2
Combo MTX+ 6 wks prednisone
(n = 32)
Arm 3
Combo MTX+ etanercept
(n = 30)
Age (years) 8.8 (4.8-12.7) 10.2 (6.6-13.9) 8.6 (4.2-12.4)
Symptom duration* (month) 7.8 (5.3-11.6) 5.9 (4.4-13.3) 8.5 (5.0-13.1)
ANA positive (%) 15 (47) 11 (34) 9 (30)
Female (%) 24 (75) 19 (59) 20 (67)
JIA category:
Oligo (persistent)
Poly articular
Psoriatic (poly)
5 (3)
22
5
3 (1)
22
7
2 (2)
24
4
VAS physician (mm) 48 (40-55) 50 (39-58) 51 (37-61)
VAS patient/parent (mm) 48 (31-58) 59 (35-74) 58 (39-71)
CHAQ (0-3) 0.88 (0.28-1.50) 0.94 (0.63-1.69) 0.88 (0.75-1.53)
No. active joints 7.5 (5.0-12.5) 7.5 (6.0-11.8) 8.5 (5.8-13.0)
No. limited joints 2 (0-4.5) 2 (1.0-3.8) 3 (1.8-5.0)
ESR (mm/hour) 6.5 (2-11) 6.0 (2-24) 9.0 (4-25)
JADAS-10 (0-40) 15.7 (13.5-20.2) 17.9 (15.2-21.9) 19.1 (13.8-23.2)
All results in medians (InterQuartile Range) unless stated otherwise;*time from first presenting symptoms to inclusion in the study
Fig. 1 Study profile of the BeSt for Kids study
Table 2 Outcome after 6 weeks and 3 months in BeSt for Kids
study
Arm 1
Sequential
monotherapy
n = 32
Arm 2
Combo MTX + 6
wks prednisone
n = 32
Arm 3
Combo
MTX+
etanercept
n = 30
p
Inactive disease
(%)* 6wks
3 mths
0 (0)
8 (25)
4 (13)
3 (9)
1 (3)
5 (17)
0.25
aACR Pedi 30 (%) 6
wks
3 mths
15 (47)
16 (50)
18 (56)
17 (53)
17 (57)
22 (73)
0.68
0.13
aACR Pedi 50 (%)
6wks
3 mths
9 (28)
10 (31)
14 (44)
12 (38)
11 (37)
16 (53)
0.56
0.19
aACR Pedi 70 (%)
6wks
3 mths
3 (9)
8 (25)
8(25)
6 (19)
6(20)
14 (47)
0.25
0.04
JADAS-10 (median)
6wks
3 mths
Δ JADAS-10
(median) 6wks
3 mths
13.9
9.0
3.2
6.9
9.6
11.5
6.6
5.7
12.4
8.2
5.0
10.2
0.12
0.25
0.012
0.22
*according to our definition of inactive disease modified to Wallace 2004
definition: no active synovitis, no fever, rash, serositis, splenomegaly or
generalized lymphadenopathy attributable to JIA. No active uveitis, ESR ≤
16 mm/h and physician’s VAS <10 mm
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patients performed better than expected by reaching
inactive disease after only three months of monother-
apy: 4 of them on SSZ and 4 on MTX (25% of all pa-
tients in arm 1). Inactive disease after 3 months was
rare in arm 2 (9%), and occurred in 17% of patients
in arm 3. Outside-of-protocol use of corticosteroids
in arm 1 occurred three times in the first three
months, these patients did not reach an ACRPedi50
or inactive disease after three months. Apparently for
today’s physicians it was hard to hold on to the
protocol dictating no additional use of steroids in the
current era of impatient doctors and demanding pa-
tients, but in this study it helped little to achieve in-
active disease.
To minimize the risk of bias of the open design, all
outcome measurements were assessed by trained re-
search nurses/physiotherapists/physicians who were
blinded to the allocated treatment strategy during entire
study period.
Limitations of our study are the relatively small
sample size because of slow inclusion rate. These
results are promising, but follow up is too short to
advocate as yet a primary start with etanercept in
DMARD naive new onset JIA patients. The BeSt for
Kids study will continue with a treat-to-target design,
with medication adjustments aiming to achieve and
maintain inactive disease, including after tapering
strategies in all three arms. Prospective data on
follow-up to 24 months in the BeSt for Kids study will
include assessment of possible radiographic joint
damage and level of physical functioning.
In conclusion, during the first 3 months of the BeSt
for Kids study patients with newly diagnosed JIA who
received initial combination therapy with methotrex-
ate and etanercept had significantly more aACR-
pedi70% responses, comparable side effects and fewer
medication changes as compared to methotrexate or
sulfasalazine alone or methotrexate and 6 weeks pred-
nisone bridging therapy. Long term follow up data on
the extension of initial treatments aiming at inactive
disease by a treat to target regime, are needed to re-
late to these initial positive results.
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0
0
0
0
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MTX +
etanercept
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